ArticleBiomaterials2022
Sustained endosomal release of a neurokinin-1 receptor antagonist from nanostars provides long-lasting relief of chronic pain.
Open access · greenAbstract read
In one paragraph
Article in Biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Bioinspired Cross-Linked Anionic Hydrogel Microparticles as Potential Adjuvants for Safe Vaccines: Colloidal-Chemical Characteristics, Morphology and Biological Properties.Gels (Basel, Switzerland) · 2026Article
- MMP1 and PRSS23 induce PARCommunications biology · 2026Article
- Nanoparticle-mediated antagonism of sustained endosomal signaling of the calcitonin receptor-like receptor provides enhanced and persistent relief of oral cancer pain.Biomaterials · 2026Article
- Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Mechanisms of Location Bias in G Protein-Coupled Receptors.Handbook of experimental pharmacology · 2026Review
- Article
- Nanomedicines targeting protease-activated receptor 2 in endosomes provide sustained analgesia.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Emerging therapeutic approaches for treating abdominal pain.Journal of the Canadian Association of Gastroenterology · 2025Review
- Polymeric and Polymer-Functionalized Drug Delivery Vectors: From Molecular Architecture and Elasticity to Cellular Uptake.Polymers · 2025Review
- Emerging treatments for chronic neuropathic pain from a cross-disease perspective: developments and applications of nanomaterials.The journal of headache and pain · 2025Review
- Diabetic neuropathy: cutting-edge research and future directions.Signal transduction and targeted therapy · 2025Review
- Pain Signaling by GPCRs and RTKs.Trends in pharmacological sciences · 2025Review
- Deciphering Pain and Pruritus in Keloids from the Perspective of Neurological Dysfunction: Where Are We Now?Biomedicines · 2025Article
- N-terminomics profiling of naïve and inflamed murine colon reveals proteolytic signatures of legumain.Journal of cellular physiology · 2025Article
- Beneath the surface: endosomal GPCR signaling.Trends in biochemical sciences · 2024Review
- Microneedle-mediated nanomedicine to enhance therapeutic and diagnostic efficacy.Nano convergence · 2024Review
- A novel microglia-targeting strategy based on nanoparticle-mediated delivery of miR-26a-5p for long-lasting analgesia in chronic pain.Journal of nanobiotechnology · 2024Article
- GPCR kinases differentially modulate biased signaling downstream of CXCR3 depending on their subcellular localization.Science signaling · 2024Article
- Aprepitant Restores Corneal Sensitivity and Reduces Pain in DED.Translational vision science & technology · 2024Article
- Lessons learned in translating pain knowledge into practice.Pain reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Rocco LatorreDepartment of Molecular Pathobiology, New York University, New York, 10010, USA; Department of Neuroscience and Physiology, Neuroscience Institute, New York University, New York, 10010, USA.
Paulina D Ramírez-GarciaMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Alan HegronDepartment of Molecular Pathobiology, New York University, New York, 10010, USA; Department of Neuroscience and Physiology, Neuroscience Institute, New York University, New York, 10010, USA.
James L GraceMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Jeffri S RetamalMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Priyank ShenoyMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Mai TranMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Luigi AurelioMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Bernard FlynnMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Daniel P PooleMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Rafael Klein-CloudDepartment of Molecular Pathobiology, New York University, New York, 10010, USA; Department of Neuroscience and Physiology, Neuroscience Institute, New York University, New York, 10010, USA.
Dane D JensenDepartment of Molecular Pathobiology, New York University, New York, 10010, USA; Bluestone Center for Clinical Research, New York University College of Dentistry, New York, 10010, USA.
Thomas P DavisAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
Brian L SchmidtDepartment of Molecular Pathobiology, New York University, New York, 10010, USA; Department of Neuroscience and Physiology, Neuroscience Institute, New York University, New York, 10010, USA; Bluestone Center for Clinical Research, New York University College of Dentistry, New York, 10010, USA.
John F QuinnMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Michael R WhittakerMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia. Electronic address: michael.whittaker@monash.edu.
Nicholas A VeldhuisMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia. Electronic address: nicholas.veldhuis@monash.edu.
Nigel W BunnettDepartment of Molecular Pathobiology, New York University, New York, 10010, USA; Department of Neuroscience and Physiology, Neuroscience Institute, New York University, New York, 10010, USA. Electronic address: nwb2@nyu.edu.
Monash University · AUNeurosciences Institute · USCenter for Clinical Research (United States) · USThe University of Queensland · AU
Funding
Targeting Endosomal Receptors for Treatment of Chronic PainR01DE029951 · NIDCR · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2020 to 2024
$4.7MProtease/PAR2/TRPV4 Axis and Oral Cancer PainR01DE026806 · NIDCR · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2018 to 2022
$3.9MEndosomal Platforms for Signaling PainR01NS102722 · NINDS · NEW YORK UNIVERSITY · PI NIGEL W BUNNETT, Brian L Schmidt · 2017 to 2026
$3.4MTrafficking-Dependent Signaling of Pain by Protease-Activated ReceptorsR01DK118971 · NIDDK · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2018 to 2021
$3.2MNIDCR NIH HHS R01 DE026806NIDCR NIH HHS R01 DE029951NIDDK NIH HHS R01 DK118971NINDS NIH HHS R01 NS102722
Abstract
Soft polymer nanoparticles designed to disassemble and release an antagonist of the neurokinin 1 receptor (NK
Indexed as
Chronic PainNeurokinin-1 Receptor AntagonistsAnimalsAprepitantEndosomesMicePolymersAprepitantNeurokinin-1 Receptor AntagonistsPolymersEndosomesNociceptionPainReceptorsSignal transduction
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.